Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INCB 59872

Drug Profile

INCB 59872

Alternative Names: INCB 059872; INCB59872

Latest Information Update: 31 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Class Antianaemics; Antineoplastics; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Ewing's sarcoma; Prostate cancer; Sickle cell anaemia

Most Recent Events

  • 10 Apr 2021 Data from preclinical studies in Acute myeloid leukaemia models presented at 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
  • 04 Aug 2020 Discontinued - Phase-I for Ewing's Sarcoma (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in Italy, United Kingdom, Spain, USA (PO)
  • 04 Aug 2020 Discontinued - Phase-I/II for Cancer (Late-stage disease) in Netherlands, Belgium, USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top